Business
Intel Stock Climbs 2.9% as AI Packaging Deals and Foundry Turnaround Spark Rally Ahead of Q1 Earnings
NEW YORK — Intel Corp. shares advanced nearly 3% in early trading Monday to $64.17 as investors bet on the chipmaker’s accelerating foundry momentum, potential billion-dollar advanced packaging wins with hyperscalers and a broader turnaround under new leadership, even as the company prepares to report first-quarter results later this month.
AFP
The Nasdaq-listed stock (INTC) extended a sharp rally that has seen shares surge more than 60% year-to-date in 2026 and hit multi-year highs in recent sessions. Trading volume remained elevated as the semiconductor giant benefited from renewed optimism around its Intel 18A process node, custom AI chip opportunities and strategic moves to regain ground against Taiwan Semiconductor Manufacturing Co. and other rivals.
Intel’s resurgence has been driven by tangible progress on its long-troubled foundry business. The company recently repurchased a 49% stake in its Fab 34 facility in Ireland from Apollo Global Management for $14.2 billion, restoring full ownership of a key advanced manufacturing asset. The move strengthens Intel’s control over capacity needed for both internal products and external foundry customers in the AI era.
Advanced packaging has emerged as an unexpected bright spot. Chief Financial Officer Dave Zinsner signaled in early April that Intel is in advanced talks with major cloud providers, including Google and Amazon, for large-scale packaging services on custom AI chips. These deals could generate the company’s first billion-dollar annual foundry revenue streams before significant wafer manufacturing ramps, with gross margins potentially reaching 40%. Intel’s EMIB and Foveros technologies offer alternatives to TSMC’s dominant CoWoS packaging, appealing to U.S.-based customers seeking domestic supply chain options amid geopolitical risks.
A landmark multi-year partnership expansion with Alphabet’s Google, announced earlier in April, further boosted sentiment. The deal focuses on next-generation AI and cloud infrastructure, helping push Intel shares to a new 52-week high around $63.39 on April 10. Additional collaboration with Elon Musk’s Terafab initiative — involving Tesla, SpaceX and xAI — has positioned Intel as a potential supplier for large-scale AI chip manufacturing projects.
Under CEO Lip-Bu Tan, who took the helm in late 2025, Intel has emphasized execution on its “five nodes in four years” roadmap. The Intel 18A process node entered high-volume manufacturing in late 2025, with the first products — including Panther Lake AI PC processors — now shipping. Clearwater Forest server CPUs and other 18A-based designs are also advancing, targeting improved power efficiency and performance for data center and edge AI workloads.
Intel’s Gaudi 3 AI accelerator and upcoming Crescent Island inference chip aim to provide cost-effective alternatives to NVIDIA’s dominance in training and inference. While Intel trails in the high-end GPU market, its x86 architecture and integrated software stack offer advantages for certain enterprise and inference use cases.
The stock’s rally has been dramatic after a brutal 2024 and early recovery in 2025. Shares have more than tripled from multi-year lows, reflecting renewed confidence in the foundry-first strategy and AI PC opportunities. Analyst upgrades have supported the move: Wells Fargo raised its price target from $45 to $55, while other firms including Jefferies and KeyCorp have lifted targets amid improving fundamentals. Consensus remains mixed, however, with many analysts holding “Hold” ratings and average targets lagging the recent price surge.
First-quarter 2026 financial results are scheduled for release after the market close on April 23, with a conference call to follow. Wall Street expects revenue around $12.3 billion to $12.6 billion, with lingering softness in some segments offset by data center strength and early 18A contributions. Investors will scrutinize gross margins, foundry operating losses and any updates on external customer wins or capital expenditure plans.
Intel’s balance sheet has strengthened in recent quarters, providing more flexibility for investments and potential share repurchases. The company continues to benefit from U.S. government support through the CHIPS Act, which has helped fund domestic fab expansions.
Challenges remain significant. Foundry profitability is still years away, with heavy capital spending required to scale 18A and future 14A nodes. Competition is fierce across client, data center and AI accelerators. Execution risks on manufacturing yields and securing external foundry customers could temper enthusiasm if progress slows.
Yet recent operational metrics have been encouraging. Intel reported improving yields on 18A, with monthly gains that could support higher volumes later in 2026. The AI PC segment, powered by new Core Ultra processors with strong neural processing units, is gaining traction as Windows on Arm alternatives and local AI capabilities drive enterprise refresh cycles.
Broader market context aided Monday’s gains. Easing geopolitical tensions and anticipation around corporate earnings helped lift sentiment for semiconductor names. Intel’s defense and government exposure has also provided some stability amid global uncertainties.
For long-term investors, Intel represents a high-stakes bet on America’s ability to compete in advanced semiconductor manufacturing. Success in foundry could transform the company from a struggling IDM into a diversified technology powerhouse with recurring revenue from external customers.
Retail enthusiasm has grown as the stock has moved from “dead money” to one of the year’s top performers. Options activity and short interest dynamics have at times amplified moves, though the recent rally has pushed technical indicators into overbought territory.
As trading progressed Monday, Intel’s modest gain reflected continued momentum rather than euphoria. The coming earnings report will serve as an important checkpoint on whether the turnaround narrative is translating into financial results.
With 18A products shipping, packaging deals in the pipeline and strategic partnerships expanding, Intel has a renewed lease on life after years of setbacks. Whether it can sustain the rally through 2026 will depend on consistent execution and the ability to convert AI hype into sustainable foundry revenue.
Analysts warn that valuation has expanded rapidly, leaving less margin for error. Still, for those who believe in the long-term importance of domestic chipmaking and Intel’s technological assets, the current setup offers a compelling risk-reward profile after the dramatic recovery from 2024 lows.
Intel’s journey from near-death experience to AI contender underscores the volatility and opportunity in the semiconductor sector. Monday’s trading suggested Wall Street is increasingly willing to give the company the benefit of the doubt as key milestones approach.
Wegovy semaglutide tablets.
Michael Siluk | Universal Images Group | Getty Images
When the Wegovy pill launched in January, telehealth provider LifeMD said its business doubled almost overnight.
LifeMD went from seeing between 300 and 400 new patients a day to 600 to 1,000 new patients a day, said CEO Justin Schreiber. He knew there would be demand, but that level of interest surprised him.
“There’s no question that the launch of oral medications has improved access,” Schreiber said.
Tens of thousands of people have started taking Novo Nordisk’s Wegovy pill in the four months since it launched in the U.S., the majority of them new to the GLP-1 category. Investors will get a fresh look at the Wegovy pill’s momentum when Novo reports first-quarter results on Wednesday.
The launch has already forced investors to rethink the opportunity in oral GLP-1s – and which company might win it. While obesity and diabetes market leader Eli Lilly launched its own pill, Foundayo, last month, early signs indicate its rollout has been more modest than the Wegovy pill’s start.
“We were all in this camp of Foundayo, Foundayo, Foundayo because Lilly was talking it up and we were also concerned about making enough peptide because Novo was still coming out of shortage,” said BMO Capital Markets analyst Evan David Seigerman.
Now, Novo’s early success has upended the expectations of some investors and analysts who expected the Danish company would fall behind its U.S. rival in the oral category, as it did in injectables.
Novo’s Wegovy pill uses the same main ingredient as its weekly shot. The company had at times struggled to produce enough of the peptide to satisfy the soaring demand for the injection, and the oral formulation required even more of it. Meanwhile, Lilly was telling investors its GLP-1 pill was easier to make and wouldn’t face the shortages that hindered the shots.
Doubts about Lilly’s lock on the market emerged last summer when the company said its pill helped people lose about 12% of their body weight, on average. Seigerman noticed Novo pounced on the opportunity and started to highlight the efficacy of oral semaglutide, the active ingredient in Novo’s Wegovy, which delivered almost 17% weight loss in a separate trial.
When the Wegovy pill was approved around the New Year, Novo and its telehealth partners rolled out a high-profile promotional blitz. Ads blanketed New York City subways and TV broadcasts. The Danish drugmaker even tapped celebrities like DJ Khaled for its first-ever Super Bowl ad.
Novo pushed the pill’s lower entry price of $149 per month and injection-like efficacy. The company used its three-month head start on Lilly to shape the narrative and combat concerns that people wouldn’t want a pill that needs to be taken first thing in the morning without food and with little water, which Novo CEO Mike Doustdar said were “a bit fueled by our competitor.”
“Well, I have news for you, this has been absolutely not the case,” Doustdar told CNBC in March. “People are really interested because it’s the most efficacious pill right now in the market.”
The Wegovy pill — and now Lilly’s own oral drug — are helping to expand the GLP-1 market, reaching patients who wouldn’t have otherwise sought treatment due to a fear of needles or difficulty accessing the injections, which used to cost much more than today’s pills for many patients.
“There’s a fair number of patients that don’t want to be stuck by the needle in the case of a vial and syringe or stung by the price,” Jamey Millar, Novo’s head of U.S. operations, said in a March interview.
People are choosing GLP-1 pills “by a huge factor” more than shots through telehealth platform Sesame, said CEO Michael Botta. He attributes the preference to the lower price of the pills versus the shots and the fact that people are more comfortable trying oral drugs than going straight to shots.
That could bring in a more diverse set of patients to the category. More men are “definitely” starting the medications than before, he said, though women still make up a majority of new patients.
Shortly after the launch, Novo said that many of the initial users were taking the lowest starter dose of the drug. Millar told CNBC that the company is closely watching how many patients move to the highest doses over the coming months.
What to watch in Novo vs. Lilly
Eli Lilly appears to have work to do to catch up to Novo.
While Novo was able to leverage the Wegovy brand recognition right out the gate, Lilly is trying to introduce introduce people to an entirely new brand. Its pill Foundayo has a different active ingredient than its best-selling weight-loss shot Zepbound. Lilly executives last week sought to reassure investors that it’s going to take time to introduce the drug to doctors and patients.
In the first few weeks of the launch, more than 20,000 people have started taking Foundayo, Lilly CEO Dave Ricks told CNBC following the company’s first-quarter earnings report. More than 1,000 people are starting the drug every day, and 80% of those patients are new to GLP-1 drugs, he said. Lilly still needs to build consumer awareness around the pill, Ricks said, adding the company hasn’t started widely advertising it on TV.
“So what we’re seeing now is basically organic demand, which is really strong to us,” Ricks said.
RBC analyst Trung Huynh said investors should wait two or three months to judge the momentum of Lilly’s Foundayo launch because there’s so much early volatility. He thinks it’ll take a year or two for the story to play out. He pointed to the market for weekly shots: prescriptions of Zepbound surpassed those for Novo’s Wegovy six months after Zepbound was introduced in the U.S., even though it launched two years later.
Because Lilly hiked its full-year sales forecast on strength across its GLP-1 business, it should take some pressure off Foundayo prescriptions in the near term, said Barclays analyst Emily Field. The company plans to start introducing Foundayo in other countries later this year and has touted the pill as the key to reaching people around the world.
Novo hasn’t disclosed any specifics around a potential launch of its Wegovy pill outside of the U.S., but in March it announced a $500 million manufacturing investment in Ireland to meet current and future demand for its oral products outside of the U.S. The European Medicines Agency is expected to approve the Wegovy pill later this year.
Investors will get a better look at the Wegovy pill’s performance this week when the company reports earnings from the first quarter it was available in the U.S. Analysts have praised the strength of the rollout, which outpaced even the launch of its shots.
Even so, Wall Street expects a significant drop in overall sales this quarter, as generic competition for the Wegovy shot threatens sales in India, China and Canada. The pill’s lower price point could also crimp U.S. sales.
Investors will be on high alert for any data related to the Wegovy pill and whether Novo stands by the gloomy forecast it issued in February, when it said sales and profits will both decline by 5% to 13% in 2026. Novo’s pipeline will also be a focus. Disappointments in the clinic have weighed on the stock, causing investors to wonder whether Novo’s pipeline is rich enough to help the company stay competitive.
And while the pills are important to both Novo and Lilly, analysts say they won’t define either company.
“Yes it’s shaking things up, but I still think Lilly has enough components to excel,” BMO’s Seigerman said. “And while Novo may win with this, they need more than one win to be the champion.”
Business
Tata Chemicals Q4 results: Cons loss widens YoY to Rs 2,132 crore on exceptional items; revenue drops 2%
The company reported an exceptional charge of Rs 1,837 crore is provided on account of impairment of goodwill in US & Rs 159 crore of deferred tax assets write off.
Profit after tax before exceptional items and NCI stood at Rs 279 crore compared to a loss of Rs 12 crore for Q4FY25, the company filing to the exchanges said.
The loss widened on a sequential basis too, as the company reported a net loss of Rs 93 crore in Q3FY25. The topline was down 3% on a quarter-on-quarter basis versus Rs 3,550 crore reported in the October-December quarter of FY26.
The company’s board also recommended a dividend of Rs 11 per share for the financial year 2025-26. The dividend, if approved by the members at the upcoming 87th Annual General Meeting (AGM), will be paid within five days of the AGM, the company filing said.
The company’s expenses in the quarter under review stood at Rs 3,660 crore versus Rs 3,644 crore in Q3FY26 and Rs 3,612 crore in Q4FY25. The expenses were made on heads like ‘Cost of materials consumed’, ’employee benefits expense’, finance cost and power and fuel.
The company reported a negative cash flow of Rs 1,459 crore as on March 31, 2026 ended period compared to Rs 568 crore as of March 31, 2025. The CFO was adjusted for depreciation and amortisation expenses, fianance cost and dividend income, among other things.The net profit margin in the reported quarter stood at -61.55% versus -1.94% in Q3FY25 and 1.91% in Q4FY25.
The company’s Earnings Before Interest, Taxes, Depreciation and Amortisation (EBITDA) stood at Rs 274 crore as compared to Rs 327 crore in Q4FY25, mainly on account of subdued pricing across all geographies and increase in fixed cost (also due to steep depreciation of Indian Rupee) as compared to Q4FY25.
Net debt (without leases) as on March 31, 2026, stood at Rs 5,961 crore.
Management commentary
R. Mukundan, Managing Director & CEO of Tata Chemicals said the global soda ash market remained oversupplied in Q4FY26, keeping prices under pressure amid geopolitical uncertainties in the Middle East. While standalone performance was supported by higher volumes and cost discipline, consolidated results were hit by weak pricing across regions, particularly in Southeast Asia, along with impairment charges in the US business.
He added that the company continues to focus on long-term growth initiatives, including the acquisition of Novabay Pte. Ltd. to expand its specialty chemicals portfolio and a Rs 100 crore investment to enhance salt capacity at Mithapur. Despite the challenging environment, Tata Chemicals remains focused on protecting margins, conserving cash flows, and maintaining a strong balance sheet to navigate the current cycle and drive sustainable value creation.
(Disclaimer: The recommendations, suggestions, views, and opinions given by the experts are their own. These do not represent the views of The Economic Times.)
NEW YORK — Oracle Corporation (NYSE: ORCL) stock draws a resounding “Buy” recommendation from Wall Street in May 2026, with consensus ratings of Moderate Buy to Strong Buy and average 12-month price targets implying 30-50% upside from current levels near $175–$183. Despite volatility from heavy AI infrastructure spending and a year-to-date pullback, the database and cloud giant’s explosive remaining performance obligations (RPO), cloud revenue growth and strategic positioning in artificial intelligence infrastructure position it as a favored long-term holding for many investors.
As of early May 2026, Oracle shares trade around $175–$182 after recovering modestly from earlier 2026 lows. The stock has faced pressure amid broader tech sector rotations and concerns over elevated capital expenditures, yet analysts overwhelmingly see current valuations as attractive given Oracle’s fundamentals and AI tailwinds.
Strong Analyst Consensus
Across 35–55 covering analysts, Oracle earns predominantly Buy or Strong Buy ratings, with very few Holds and minimal Sells. Average 12-month price targets range from $220 to $260, with highs reaching $400 and lows near $155–$160. This suggests substantial potential upside, with some models projecting even higher returns if cloud and AI momentum accelerates.
Firms like Guggenheim, Bank of America and others maintain bullish stances, citing Oracle’s massive RPO backlog — which surged over 300% year-over-year in recent quarters — as evidence of sustained demand for its cloud offerings.
Fiscal 2026 Performance and Earnings Highlights
Oracle has delivered solid results through its fiscal year. In Q3 FY2026 (reported March 2026), the company posted revenue of about $17.19 billion (up ~22% YoY) and beat EPS estimates. Remaining Performance Obligations reached $553 billion, up 325% year-over-year, signaling strong future revenue visibility driven by cloud infrastructure and AI-related deals.
Earlier quarters showed cloud revenue growth exceeding 25–28%, fueled by demand for Oracle Cloud Infrastructure (OCI) used in large-scale AI training and deployment. However, higher capex for data centers has weighed on near-term margins and free cash flow, contributing to stock volatility.
Bull Case: AI and Cloud Leadership
Supporters highlight Oracle’s transformation into a major cloud player. Its focus on high-performance computing for AI, strategic partnerships and ability to win large enterprise contracts differentiate it from competitors. Analysts project continued double-digit revenue growth, with some bull scenarios seeing the stock reaching $300–$344 within 12–18 months if RPO converts efficiently.
Valuation remains reasonable relative to growth prospects, with forward multiples that many view as discounted compared to pure-play cloud peers. Dividend growth and share repurchases add to shareholder returns.
Risks and Bear Concerns
Critics point to execution risks around heavy AI spending, rising debt levels and potential delays in monetizing infrastructure investments. A tougher macroeconomic environment or slower AI adoption could pressure results. Some analysts trimmed targets after recent quarters, citing margin compression.
Short-term volatility remains a factor, with the stock sensitive to quarterly guidance and broader tech sentiment. A deeper market correction could test lower support levels.
Investment Considerations for 2026
For growth-oriented investors, Oracle offers exposure to enterprise software stability plus high-growth cloud and AI opportunities. Long-term holders may benefit from dollar-cost averaging during dips. Those concerned about capex timing might prefer a more cautious allocation or wait for clearer cash flow inflection.
Financial advisors often recommend tech holdings like Oracle as part of diversified portfolios, especially for those seeking AI adjacency without pure-play startup risk. Position sizing should reflect individual risk tolerance given sector volatility.
Broader Market Context
Oracle’s story mirrors other Big Tech names balancing massive AI investments with profitability. Its hybrid cloud-database strengths provide a moat in enterprise markets where data sovereignty and performance matter. As AI infrastructure demand grows, Oracle is well-placed to capture share.
Upcoming earnings, macroeconomic data and AI spending trends will influence sentiment through the rest of 2026. Analysts will closely watch cloud bookings, margin trends and progress on capital efficiency.
Conclusion: Favored as a Buy for Most Investors
The overwhelming Wall Street consensus tilts strongly toward buying Oracle stock in 2026. Structural growth drivers in cloud and AI, combined with a solid backlog and reasonable valuation, outweigh near-term spending concerns for most analysts. While risks around execution and macro conditions exist, current levels appear attractive for those with a medium-to-long-term horizon.
Investors should perform their own research, consider diversification and consult professionals. Oracle is not without volatility, but the balance of evidence supports its role as a core tech holding with meaningful upside potential as AI infrastructure spending translates into sustained revenue and profits.
Arbitrage Trader, aka Denislav Iliev has been day trading for 15+ years and leads a team of 40 analysts. They identify mispriced investments in fixed-income and closed-end funds based on simple-to-understand financial logic.
Denislav leads the investing group Trade With Beta, features of the service include: frequent picks for mispriced preferred stocks and baby bonds, weekly reviews of 1200+ equities, IPO previews, hedging strategies, an actively managed portfolio, and chat for discussion. Learn more.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in AXS.PR.E over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Presentation
Wolf E. Regener
President, CEO & Director
Different attendees. Pauline, can you see the attendees or not?
Unknown Executive
I don’t see anyone that’s on your list that’s attended. I just see the ones that I preregistered that were on for the call.
Wolf E. Regener
President, CEO & Director
So I’ve got 2 phone numbers and then a few names.
Unknown Executive
I don’t see them on here. [indiscernible].
Unknown Executive
Tab, you might be able to see you can’t see that.
Unknown Executive
Okay. I can see Jon. I can register Jay. Thank you. And Peter Nelson. And I also see is that David?
Unknown Executive
Yes, I think he’s one of the people that preregistered.
Unknown Executive
Rachel, thank you for joining. I do see 2 telephone numbers. Can you identify yourself, please? yourself off mute.
Wolf E. Regener
President, CEO & Director
Yes, just to [indiscernible].
Unknown Executive
Someone else has just recently dialed in. Could you please identify yourself?
Wolf E. Regener
President, CEO & Director
You need to go off mute, please.
Unknown Executive
I don’t know if you want me to start.
Wolf E. Regener
President, CEO & Director
I think maybe talking to counsel, I’m not sure.
Unknown Executive
Wolf, did we gain another caller as well? We did.
Evan Templeton
Are those showing up under the way that we logged on or differently?
Wolf E. Regener
President, CEO & Director
Differently.
Evan Templeton
Okay. Because I’m seeing the numbers up with another one just joined.
Wolf E. Regener
President, CEO & Director
No, just out of
Lauren Bech-Hansen
So hello, everyone. Thank you for joining Organto Foods’ Fiscal 2025 Review and Business Update Webinar. My name is Lauren Bech-Hansen, and I will be monitoring today’s session. We’ll begin with a brief presentation from Steve Bromley, CEO, and Co-Chair of Organto Foods, who will walk through the company’s fiscal 2025 operational highlights, financial results and outlook for 2026. Following the presentation, we’ll move into a live Q&A session.
[Operator Instructions] Before we begin, I’ll note that today’s discussion may include forward-looking information and forward-looking statements within the meaning of applicable Canadian securities law. These statements may relate to Organto’s expectations, plans, objectives, strategies, financial outlook, anticipated growth, operating performance, market opportunities, expansion plans and other future developments.
Forward-looking statements are based on management’s current expectations, assumptions, estimates and beliefs and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. For a discussion of these risks, assumptions and uncertainties, please refer to Organto’s public disclosure documents, including its MD&A available under the company’s profile on SEDAR.
Today’s discussion may also reference certain non-IFRS financial measures, including EBITDA or adjusted EBITDA. These measures do not have standardized meanings under IFRS and may not be comparable to similar measures used by other companies. Please refer to Organto’s public disclosure documents for additional information, including reconciliations where applicable.
Nothing discussed in today’s session to be considered investment, financial, legal or tax advice. Organto undertakes no obligation to update forward-looking statements, except as required by applicable law. With that, thank you, everyone, for joining us today.
I’m pleased to turn the
If what you want from your index fund is access to the latest hot stocks, you’re in luck. The passive funds holding trillions of dollars of 401(k)s and other investments are rushing to change their rules as the IPOs of SpaceX, OpenAI and Anthropic draw closer.
The latest, on Thursday, was a proposal from S&P to drop the requirement to make a profit and wait a year for initial public offerings to get into the flagship S&P 500.
Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
In APSEZ, Capital Group International All Countries Equity Trust acquired 2.46 crore shares worth Rs 4,021 crore at Rs 1,632.45 apiece. It was joined by Capital Income Builder, which bought shares worth Rs 617 crore, and Europacific Growth Fund, which picked up shares valued at Rs 2,848 crore. The seller in all these transactions was Worldwide Emerging Market Holding Limited, indicating a sizeable stake transfer between institutional investors.
In TMCV, BNP Paribas purchase 7.18 lakh shares worth Rs 29 crore at Rs 405.80 each, while Goldman Sachs offloaded an equivalent stake. Similarly, Siemens Energy India witnessed a Rs 29 crore block deal, with BNP Paribas acquiring 89,240 shares at Rs 3,256.80 apiece from Goldman Sachs Bank Europe SE.
Adani Ports shares today ended at Rs 1,742.60, gaining by Rs 85.30 or 5.15%. The stock today hit its 52-week high of Rs 1,748.60 on the NSE. APSEZ shares have gained nearly 40% over the past 12 months.
Shares of Tata Motors today ended at Rs 412.90, gaining by Rs 3 or 0.73% while Siemens Energy India settled at Rs 3,320.70, gaining 41.90 or 1.28%.
Domestic stock markets ended higher on Monday with BJP all set to win states of West Bengal and Assam and wrest back the Union Territory of Puducherry. Sectorally, financials, pharma and metal let the bulls. While the 50-stock Nifty surged 121.75 points or 0.51% to finish at 24,119.30, Sensex gained 0.46% points or 355.90 points to settle at 77,269.40.
Also read: Mauritius-based entity sells Rs 289 crore worth shares in Emcure Pharmaceuticals via block deal; Norges Bank acquirer
(Disclaimer: The recommendations, suggestions, views, and opinions given by the experts are their own. These do not represent the views of The Economic Times.)
Bret Jensen has over 13 years as a market analyst, helping investors find big winners in the biotech sector. Bret specializes in high beta sectors with potentially large investor returns.Bret leads the investing group The Biotech Forum, in which he and his team offer a model portfolio with their favorite 12-20 high upside biotech stocks, live chat to discuss trade ideas, and weekly research and option trades. The group also provides market commentary and a portfolio update every weekend. Learn More.
Analyst’s Disclosure: I/we have a beneficial long position in the shares of AMZN either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Calamos Investments President and CEO John Koudounis analyzes the strength of the U.S. economy despite Iran-driven oil risks and weighs in on Kevin Warsh’s expected Fed takeover on ‘Mornings with Maria.’
Markets may face near-term volatility tied to oil prices and geopolitical tensions, but underlying economic strength and the prospect of lower interest rates could fuel a powerful next leg higher, according to a market expert.
Calamos Investments President and CEO John Koudounis joined FOX Business’ Maria Bartiromo on “Mornings with Maria” to discuss market resilience and why he sees further upside despite ongoing uncertainty.
Markets anticipate possible Fed rate cuts amid easing inflation. (istock / Getty Images)
Koudounis pointed to strong corporate earnings and supportive policy dynamics as key drivers behind recent market gains, noting that “the underlying economy is pretty strong” and that “earnings are doing really well.” He added that factors like tax-related cash flow are also helping support consumer activity and sentiment.
That backdrop, he argued, is helping markets look past short-term disruptions tied to rising oil prices and Middle East tensions. While “you’re going to see the market volatile because of the price of oil,” Koudounis said he expects those pressures to ease, with energy markets eventually stabilizing and supporting broader growth.
Panelists EJ Antoni and Kaylee McGhee White analyze President Donald Trump’s economic wins and May Day protests on ‘The Bottom Line.’
“When that happens, we’re off to the races again,” he said, adding that “the market really, really wants to run.”
Looking ahead, Koudounis emphasized that monetary policy could play a critical role in accelerating economic momentum. If inflation remains contained, he expects interest rates to move lower, creating a more supportive environment for growth.
FED’S FAVORED INFLATION GAUGE REMAINED ELEVATED IN MARCH
“I think we’re going to have rates being lowered,” Koudounis said. “And I think that’s going to continue one of the biggest explosions in the economy that we’ve seen.”
Panelists Mark Penn and Reince Priebus discuss Americans’ perceptions of the U.S. economy amid the Iran War on ‘Kudlow.’
Despite ongoing uncertainty, including geopolitical risks and the upcoming midterm elections, he maintained a bullish outlook, noting that “we’re in a great position where we can handle this crisis” and that market performance remains “incredible” given current conditions.
FEDERAL RESERVE LEAVES INTEREST RATES UNCHANGED AS POWELL’S CHAIRMANSHIP NEARS END
He added that the broader setup heading into and beyond the midterm elections is likely to remain “very, very positive for the markets.”
Netflix’s Record-Breaking ‘Jurassic World’ Series Reveals What the Movies Keep Missing
Panthers add longtime S Mike Adams to coaching staff
DHS Demanded Google Surrender Data on Canadian’s Activity, Location Over Anti-ICE Posts
Manchester United reach agreement with Casemiro over contract clause amid transfer speculation
US brings back mandatory military draft registration
Steven Gerrard disagrees with Gary Neville over ‘shock’ Chelsea and Arsenal claim | Football
-
Politics7 days agoDrax board avoid their own AGM, accused of greenwashing & environmental racism
-
Fashion6 days agoKylie Jenner’s KHY Enters a New Era with ‘Born in LA’
-
NewsBeat1 day agoChannel 5 – All Creatures Great and Small series 7 new post
-
Tech7 days agoImages of Samsung’s rumored smart glasses have leaked
-
Tech3 days agoTrump’s 25% EU auto tariff breaches Turnberry Agreement that also covers semiconductors and digital trade
-
Business6 days agoMost Commercial Energy Audits Miss the Real Losses
-
Crypto World6 days agoCFTC’s AI will review U.S. crypto registration applications, chairman tells CoinDesk
-
Sports3 days agoPaul Scholes issues Marcus Rashford reality check as agreement emerges over Man United star
-
Business5 days agoBarclay Brothers Avoid Bankruptcy: HSBC Drops High Court Petitions After IVA Deal
-
Business5 days agoTesla Officially Registers Elon Musk’s Stock: What Investors Need to Know
-
Tech6 days agoGet Ready for More Brain-Scanning Consumer Gadgets
-
Crypto World6 days agoRobinhood Phishing Scam Exploits Gmail Dot Feature to Bypass Security
-
Crypto World7 days agoGmail Dot Trick Underpins Robinhood Phishing, Sending Real-Looking Emails
-
Entertainment7 days agoSister Wives: Janelle Posts New Scary Warning
-
Entertainment7 days agoMichael Jackson’s Biopic Excluded Abuse Allegations For $25M
-
Business4 days agoTwo Powerball Tickets Split $143 Million Jackpot in Indiana and Kansas
-
Business7 days agoSuperdry co-founder accused of raping woman
-
Crypto World7 days agoMeme Coin Based on White House Shooter Conspiracy Rallies 320%
-
Tech7 days agoYouTube TV’s Multiview Feature Just Got A Game-Changing Upgrade
-
Business7 days ago
Opus Genetics president Benjamin Yerxa sells $39,121 in stock
You must be logged in to post a comment Login